Millendo Therapeutics develops           novel, disease-modifying treatments         for endocrine diseases caused by   hormone dysregulation.

Learn More

July 27, 2016
Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome
Read More >>

June 23, 2016
Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board 
Read More >>